Disgust affects TNF-α, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder

Psychoneuroendocrinology

Volumn 35, Issue 6, 2010, Pages 906-911

  Fluitman, Sjoerd B A H A ^a   Denys, Damiaan A J P ^a,b   Heijnen, Cobi J ^c   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Disgust; IL 6; Neuroendocrine; Obsessive compulsive disorder; Provocation; TNF

Indexed keywords

CATECHOLAMINE; HYDROCORTISONE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LEUKOCYTE; MALE; NORADRENALIN BLOOD LEVEL; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; SCORING SYSTEM; VISUAL ANALOG SCALE;

ADULT; EMOTIONS; EPINEPHRINE; FEMALE; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; MALE; NOREPINEPHRINE; OBSESSIVE-COMPULSIVE DISORDER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953022547     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2009.12.005     Document Type: Article

References (42)

1. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000, 35:151-159.
2. Balschun D., Wetzel W., del Rey A., Pitossi F., Schneider H., Zuschratter W., Besedovsky H.O. Interleukin-6, a cytokine to forget. FASEB J. 2004, 18:1788-1790.
3. Bastani B., Nash J.F., Meltzer H.Y. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch. Gen. Psychiatry 1990, 47:833-839.
4. Benkelfat C., Mefford I.N., Masters C.F., Nordahl T.E., King A.C., Cohen R.M., Murphy D.L. Plasma catecholamines and their metabolites in obsessive-compulsive disorder. Psychiatry Res. 1991, 37:321-331.
5. Brambilla F., Perna G., Bellodi L., Arancio C., Bertani A., Perini G., Carraro C., Gava F. Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol. Psychiatry 1997, 42:976-981.
6. Carpenter L.L., Heninger G.R., McDougle C.J., Tyrka A.R., Epperson C.N., Price L.H. Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania. Psychiatry Res. 2002, 112:257-262.
7. Catapano F., Monteleone P., Fuschino A., Maj M., Kemali D. Melatonin and cortisol secretion in patients with primary obsessive-compulsive disorder. Psychiatry Res. 1992, 44:217-225.
8. Cavedini P., Gorini A., Bellodi L. Understanding obsessive-compulsive disorder: focus on decision making. Neuropsychol. Rev. 2006, 16:3-15.
9. De Geus G.F., Denys D.A., Sitskoorn M.M., Westenberg H.G. Attention and cognition in patients with obsessive-compulsive disorder. Psychiatry Clin. Neurosci. 2007, 61:45-53.
10. Denys D., Fluitman S., Kavelaars A., Heijnen C., Westenberg H. Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinology 2004, 29:945-952.
11. Denys D., Fluitman S., Kavelaars A., Heijnen C., Westenberg H. Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive-compulsive disorder. Psychoneuroendocrinology 2006, 31:355-360.
12. Elenkov I.J., Chrousos G.P. Stress system - organization, physiology and immunoregulation. Neuroimmunomodulation 2006, 13:257-267.
13. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 2000, 52:595-638.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV Disorders (SCID-I) 1996, American Psychiatric Press Inc., Washington, DC.
15. Fluitman, S.B., Denys D., Vulink, N., Schutters, S., Heijnen, C., Westenberg, H., Lipopolysaccharide induced cytokine production in obssesive-compulsive disorder and generalized anxiety disorder. Psychiatry Res, in press, doi:10.1016/j.psychres.2009.05.008.
16. Goodman W.K., Price L.H., Delgado P.L., Palumbo J., Krystal J.H., Nagy L.M., Rasmussen S.A., Heninger G.R., Charney D.S. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch. Gen. Psychiatry 1990, 47:577-585.
17. Hollander E., DeCaria C., Nitescu A., Cooper T., Stover B., Gully R., Klein D.F., Liebowitz M.R. Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Res. 1991, 37:161-177.
18. Hong S.B., Shin Y.W., Kim S.H., Yoo S.Y., Lee J.M., Kim I.Y., Kim S.I., Kwon J.S. Hippocampal shape deformity analysis in obsessive-compulsive disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257:185-190.
19. Jenike M.A. An update on obsessive-compulsive disorder. Bull. Menninger Clin. 2001, 65:4-25.
20. Kluge M., Schussler P., Kunzel H.E., Dresler M., Yassouridis A., Steiger A. Increased nocturnal secretion of ACTH and cortisol in obsessive-compulsive disorder. J. Psychiatr. Res. 2007, 41:928-933.
21. Kohl C., Sperner-Unterweger B. IDO and clinical conditions associated with depressive symptoms. Curr. Drug Metab. 2007, 8:283-287.
22. Konuk N., Tekin I.O., Ozturk U., Atik L., Atasoy N., Bektas S., Erdogan A. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive-compulsive disorder. Mediators Inflamm. 2007, article ID 65704.
23. Lestage J., Verrier D., Palin K., Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav. Immun. 2002, 16:596-601.
24. Maes M., Meltzer H.Y., Bosmans E. Psychoimmune investigation in obsessive-compulsive disorder: assays of plasma transferrin IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations. Neuropsychobiology 1994, 30:57-60.
25. Marazziti D., Presta S., Pfanner C., Gemignani A., Rossi A., Sbrana S., Rocchi V., Ambrogi F., Cassano G.B. Immunological alterations in adult obsessive-compulsive disorder. Biol. Psychiatry 1999, 46:810-814.
26. McHale N.G. Lymphatic innervation. Blood Vessels 1990, 27:127-136.
27. Millet B., Touitou Y., Poirier M.F., Bourdel M.C., Hantouche E., Bogdan A., Olie J.P. Plasma melatonin and cortisol in patients with obsessive-compulsive disorder: relationship with axillary temperature, physical activity, and clinical symptoms. Biol. Psychiatry 1998, 44:874-881.
28. Monteleone P., Catapano F., Fabrazzo M., Tortorella A., Maj M. Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder. Neuropsychobiology 1998, 37:182-185.
29. Monteleone P., Catapano F., Tortorella A., Di Martino S., Maj M. Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment. Psychoneuroendocrinology 1995, 20:763-770.
30. Mossner R., Lesch K.P. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun. 1998, 12:249-271.
31. Muller J., Roberts J.E. Memory and attention in obsessive-compulsive disorder: a review. J. Anxiety Disord. 2005, 19:1-28.
32. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
33. Pickering M., O'Connor J.J. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog. Brain Res. 2007, 163:339-354.
34. Rauch S.L., Wedig M.M., Wright C.I., Martis B., McMullin K.G., Shin L.M., Cannistraro P.A., Wilhelm S. Functional magnetic resonance imaging study of regional brain activation during implicit sequence learning in obsessive-compulsive disorder. Biol. Psychiatry 2007, 61:330-336.
35. Ravindran A.V., Griffiths J., Merali Z., Anisman H. Circulating lymphocyte subsets in obsessive-compulsive disorder, major depression and normal controls. J. Affect. Disord. 1999, 52:1-10.
36. Rontgen P., Sablotzki A., Simm A., Silber R.E., Czeslick E. Effect of catecholamines on intracellular cytokine synthesis in human monocytes. Eur. Cytokine Netw. 2004, 15:14-23.
37. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33.
38. Swedo S.E., Leonard H.L., Garvey M., Mittleman B., Allen A.J., Perlmutter S., Lougee L., Dow S., Zamkoff J., Dubbert B.K. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am. J. Psychiatry 1998, 155:264-271.
39. van der Poll P.T., Jansen J., Endert E., Sauerwein H.P., van Deventer S.J. Noradrenaline inhibits lipopolysaccharide induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect. Immun. 1994, 62:2046-2050.
40. van Groenestijn M.A., Akkerhuis G.W., Kupka R.W., Schneider N., Nolen W.A. Gestructureerd Klinisch Interview Voor De Vaststelling Van DSM-IV as-I Stoornissen (SCID-I) 1999, Swerts & Zeitlinger, Lisse.
41. Weizman R., Gil-Ad I., Hermesh H., Munitz H., Laron Z. Immunoreactive beta-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder. Clin. Neuropharmacol. 1990, 13:297-302.
42. Westenberg H.G., Fineberg N.A., Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr. 2007, 12:14-27.